NUJS Kolkata professor Shamnad Basheer, who is the HRD ministry’s chair professor for intellectual property, argued over two days in his first-of-its-kind academic intervention in the landmark Novartis-Glivec patent hearing in the Supreme Court.
Swiss drug maker Novartis had approached the SC in September when it was refused a patent for cancer drug Glivec which is sold by India’s generic drug makers to reportedly 1.2 billion Indians and to poorer nations across the world.
Basheer argued before justices Aftab Alam and Ranjana Desai that even though Novartis didn’t satisfy the test to patent Glivec, excessive pricing can also not be a ground to revoke a patent. [Spicy IP]
In August, pharma company Natco had filed for defamation against Basheer in the Delhi high court, claiming that its reputation was harmed by Basheer’s comments in his entry in SpicyIP on the company’s ongoing legal battle.
NB: By reading the comments you agree that they are the personal views and opinions of readers, for which Legally India has no liability whatsoever. Because anonymous comments may be biased or unreliable, you agree that you will not allow any comment(s) to affect your estimation of any person(s) or organisation(s). If you believe a comment is inappropriate, please click 'Report to administrator' below the comment with your objection and we will review it as soon as practicable.